TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB41168

Peptide_Name

maximin4

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb dbACP iACP-DRLF

Sequence_Type

standard

Has_Modification No

Description A 26-aa standard natural anticancer peptide sequence curated from AntiCP 2.0, CancerPPD 2.0, Peptipedia, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

GIGVLLSAGKAALKGLAKVLAEKYAN-NH2

FASTA

>TPDB41168|Anticancer|length=26
GIGVLLSAGKAALKGLAKVLAEKYAN-NH2

Formula C117H203N31O32

Absent Amino Acids RDCQHMFPTW

Common Amino Acids A

Mass 2556.09

PI 10.31

Basic Residues 4

Acidic Residues 1

Hydrophobic Residues 15

Net Charge +3

Boman Index 1.64

Hydrophobicity 0.631

Aliphatic Index 135.38

Half Life

Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 1490

Absorbance 280nm 58.29

Polar Residues 3

number

6

A

0

R

1

N

0

D

0

C

1

E

0

Q

4

G

0

H

1

I

5

L

4

K

0

M

0

F

0

P

1

S

0

T

0

W

1

Y

2

V

Amino Acid Distribution

A: 6 R: 0 N: 1 D: 0 C: 0 E: 1 Q: 0 G: 4 H: 0 I: 1 L: 5 K: 4 M: 0 F: 0 P: 0 S: 1 T: 0 W: 0 Y: 1 V: 2

Length

26

Formula

C117H203N31O32

Mass

2556.09

PI

10.31

Net Charge

+3

Boman Index

1.64

Hydrophobicity

0.631

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Bombina maxima

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=24.2 µg/ml

Detail Source Activity Anticancer

Activity Measurement 24.2 µg/mL

Target

Cancer Type Leukemia Cancer

Cell Line C8166

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2001

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 =53.4 µg/ml

Detail Source Activity Anticancer

Activity Measurement 53.4 µg/mL

Target

Cancer Type Leukemia Cancer

Cell Line MOLT-4

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2001

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 =>50 µg/ml

Detail Source Activity Anticancer

Activity Measurement >50 µg/mL

Target

Cancer Type Bladder Cancer

Cell Line BIU-87

Tissue Affected Bladder

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2001

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=>50 µg/ml

Detail Source Activity Anticancer

Activity Measurement >50 µg/mL

Target

Cancer Type Bladder Cancer

Cell Line T-24

Tissue Affected Bladder

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2001